Saltar al contenido
Merck

Core-binding factor beta is required for osteoblast differentiation during fibula fracture healing.

Journal of orthopaedic surgery and research (2021-05-16)
Tuanmao Guo, Yanli Xing, Zhongning Chen, Xianhong Wang, Haiyun Zhu, Lan Yang, Yong Yan
RESUMEN

Growing evidence has implicated core-binding factor beta (Cbfb) as a contributor to osteoblast differentiation, which plays a key role in fracture healing. Herein, we aimed to assess whether Cbfb affects osteoblast differentiation after fibula fracture. Initially, we established a Cbfb conditional knockout mouse model for subsequent studies. Immunohistochemical staining was conducted to detect the expression of proliferating cell nuclear antigen (PCNA) and collagen II in the fracture end. Next, we isolated and cultured osteoblasts from specific Cbfb conditional knockout mice for BrdU analysis, alkaline phosphatase (ALP) staining, and von Kossa staining to detect osteoblast viability, differentiation, and mineralization, respectively. Western blot analysis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to detect the expression of osteoblast differentiation-related genes. The Cbfb conditional knockout mice exhibited downregulated expression of PCNA and collagen II, reduced ALP activity, and mineralization, as well as diminished expression of osteoblast differentiation-related genes. Further, Cbfb knockout exerted no obvious effects on osteoblast proliferation. Overall, these results substantiated that Cbfb could promote fibula fracture healing and osteoblast differentiation and thus provided a promising therapeutic target for clinical treatment of fibula fracture.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido L-ascórbico, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, ≥5,500 DEA units/mg protein